Today, the study "Use of a Schelin Catheter for analgesia during Rezum treatment of the prostate" was published online in the journal Prostate Cancer and Prostatic Diseases.

In the renowned journal Prostate Cancer and Prostatic Diseases, a study by the Italian urologists Giampaolo Siena, Francesco Sessa and Luca Cindolo is published today with the title "Use of a Schelin Catheter for analgesia during Rezum treatment of the prostate".

To further improve water vapor therapy, they have evaluated the benefits and feasibility of transurethral intraprostatic anesthesia (TUIA) using ProstaLund's Schelin Catheter. They registered 20 men with LUTS due to BPH, who underwent water vapor therapy using TUIA via Schelin Catheter. Before the procedure, patients were asked to rate their pain on a numerical rating scale (NRS) numbered 0–10: where 0 is "No pain" and 10 is "Worst pain". Median NRS scores ranged from 0 to 3. No peri-operative procedure-related complications were reported.

In the study, they write, among other things, that "This simple and effective approach showed several significant advantages from no or minimal patient discomfort to less theater and faster recovery time. ", "TUIA allows a further step forward towards micro-invasiveness" and "In our experience, this type of local anesthesia was safe and feasible. It shows full operative and postoperative pain control. Moreover, it allows a further shortening of hospitalization and treatment time. "

"The Schelin Catheter makes it possible to effectively administer local anesthesia into the prostate in a simple and sterile way. Dr. Siena's study shows that urologists can move the water vapor treatments from resource-intensive operating theaters to policlinical settings. Our product will revolutionize urology care around the world.", says CEO Johan Wennerholm in a comment.

For further information, please contact:

Johan Wennerholm,  CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company’s lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Attachments

First study where Schelin Catheter® was used before water vapor therapy published today

© Modular Finance, source Nordic Press Releases